Event overview and recent share performance

Charles River Laboratories International (CRL) has drawn investor attention after a period of weaker share performance, with the stock showing a 0.7% decline over the past day and a 2.4% decline over the past week.

Those short term moves sit alongside a 5.2% decline over the past month and a 21.2% decline over the past 3 months. The shares are still up 40.0% over the past year and down 51.6% over 5 years.

The 39.9% 1 year total shareholder return contrasts with the weaker recent share price returns. This suggests that momentum has cooled and investors may be reassessing growth prospects and risk after a stronger prior run.

If you are comparing CRL with other health focused names using advanced computing and data, it could be worth scanning opportunities in 33 healthcare AI stocks

With Charles River Laboratories shares down in recent months but still delivering a 39.9% 1 year total return, investors may ask whether this recent weakness is a genuine opening or whether the market is already pricing in future growth.

Most Popular Narrative: 47.1% Undervalued

According to a widely followed narrative, Charles River Laboratories has a fair value of $313.61 per share compared with the last close at $165.78, implying a large valuation gap that hinges on future earnings and margin assumptions.

The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier. On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M] At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry. However, the deeper implication is far more significant. The deal effectively expands and secures access to NHP supply, highlighting how critical primate availability has become in modern drug development. In other words, this acquisition reveals one of the hidden bottlenecks in the pharmaceutical research ecosystem: the supply of non-human primates.

Want to understand why this view sees so much upside? The narrative leans on higher future profitability, firmer margins, and a richer earnings multiple than the market is currently implying.

Result: Fair Value of $313.61 (UNDERVALUED)

However, this upside story still faces real pressure points, including execution risk around integrating K.F. (Cambodia) and ongoing ethical or regulatory scrutiny of non human primate use.

Another view: cash flows paint a cooler picture

That $313.61 fair value narrative suggests plenty of upside, but the SWS DCF model tells a different story. On this view, CRL at $165.78 is trading above an estimated future cash flow value of $133.85, which flags less upside and more valuation risk than the narrative implies. So which set of assumptions do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment split between upside potential and valuation risk, this is a moment to look at the numbers yourself and decide where you stand. To weigh those concerns and positives side by side, start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If CRL has caught your attention, do not stop here. Fresh ideas across sectors can help you build a more resilient and well rounded portfolio.

• Spot potential value opportunities early by reviewing companies highlighted in the 51 high quality undervalued stocks.
• Focus on resilience by checking out businesses featured in the 67 resilient stocks with low risk scores.
• Hunt for under followed opportunities by scanning the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.